BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks with high potential. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported total revenues of $825 million in fiscal Q2 2025, up 16% year-over-year and up 17% year-over-year at constant currency. GAAP diluted earnings per share (EPS) for the quarter reached $1.23.
In a report released on September 17, Christopher Raymond from Raymond James maintained a Buy rating on BioMarin Pharmaceutical Inc. and set a price target of $85.00.
In addition to Raymond James, Wedbush’s Yun Zhong also expressed bullish sentiments for BioMarin Pharmaceutical Inc. in a report released on September 8, assigning the stock a Buy rating. However, the same day, H.C. Wainwright initiated coverage of the stock with a Hold rating and a $60 price target.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
